Figure 6
Fluorescence spectroscopy of FITC-Dextran. (A) Fluorescence spectra recorded in urine samples collected before (dotted grey line) and 2 h after (solid blue line) oral ingestion of 1 g FITC-Dextran (commercial product). (B) Fluorescence spectra observed in aqueous solutions of commercial and synthesised (2.5 eq) FITC-Dextrans demonstrating a 3.7 × increase in fluorescence intensity in the synthesised product. Spectra were normalised according to the concentration of each solution (6.9 × 10–4 mg/ml for the commercial product, 1.6 × 10–4 mg/ml for the synthesised product), with the volume used in each measurement kept constant (2 ml).
